Subscribe
shutterstock_418900891_jejim
jejim / Shutterstock.com
29 November 2022AmericasStaff writer

Tribal business settles Stanford opioid treatment clash

Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Stanford University enters licence agreement for EGF technology
5 January 2018   Stanford University has entered into a licensing agreement with Madenco Biosciences to develop and commercialise patented epidermal growth factor wound healing technology.
Big Pharma
Indivior appeal fails to stop generic opioid addiction challenge
15 July 2019   The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Stanford University enters licence agreement for EGF technology
5 January 2018   Stanford University has entered into a licensing agreement with Madenco Biosciences to develop and commercialise patented epidermal growth factor wound healing technology.
Big Pharma
Indivior appeal fails to stop generic opioid addiction challenge
15 July 2019   The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.

More on this story

Americas
Stanford University enters licence agreement for EGF technology
5 January 2018   Stanford University has entered into a licensing agreement with Madenco Biosciences to develop and commercialise patented epidermal growth factor wound healing technology.
Big Pharma
Indivior appeal fails to stop generic opioid addiction challenge
15 July 2019   The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?